Philippe Depeille is a researcher and Lecturer in toxicology at the school of pharmacy. After earning his PhD in oncology and toxicology field at the university of Montpellier in 2005, he took a postdoctoral position in Dr Duesbery’s lab (MI, USA) where he worked on tumor vascularization and the use of Anthrax toxin as an anti-angiogenic agent. Then he joined Dr Roose lab at the university of California San Francisco (UCSF) as a staff scientist where he worked on cellular signaling in epithelial cells and solid tumors. Among others, Dr Depeille highlighted new regulatory mechanism in the EGFR-RAS pathway explaining resistance to targeted therapies. Thus, he discovered a response prognostic marker to anti-EGFR treatment leading to a better selection of colorectal cancer patients. From 2012, his works brought him to develop approaches such as 3D culture and organoids. Notably he has participated in setting up the 3D culture and organoid platform at UCSF where he has supervised and coordinated different scientific projects. His research led to a start-up creation (Seal Biosciences, CA, USA). After over 15 years of research in United States, Dr Depeille joined the F16 team in 2022. In collaboration with chemists, his work focuses on new therapeutic target identification, dissecting cellular mechanisms of action and investigating new combination therapies against cancer. https://orcid.org/0000-0002-5650-5521